Member Info for Alwaysraining

Genuine query. Is it unusual for FAB not to respond to queries? Have there been any instances of this is the past (i.e., not answering queries and then news quickly following)?

Agree with comments on timings. Frustrating but equally the role of the BOD is to act in the best interests of the company and shareholders in the longer term. That may conflict with what some of us want in the shorter term. Inking a deal with NCI may unlock some other contracts. A question I have is whether we will hear/receive details of the inking of a provisional NCI deal or whether it will be radio silence until NIH approval process is complete. Anyone any thoughts?

Thanks that’s helpful

Pickedpeck

Thanks, this is v helpful. The comment re the legacy institutional seller, is that your conclusion or was that hinted at during the speech/q&a? It does explain what is otherwise quite baffling activity given the dog trial update

Pickedpeck - thanks for this and your earlier posts. Very helpful

Genuinely hope you are correct ( and thanks for reposting the RNS). However, at this stage it is hope. I would be happier if Eric gave an interview today to explain the RNS but not holding my breath

The disconnect between this RNS and the interview Eric gave just a couple of weeks ago is huge. Given the discount to share price of previous share offerings, a new share issue of up to nearly 40% of the current share capital could be seriously detrimental to current shareholders. Can’t overstate how disappointing this is.

I’m new to this forum but I’ve been invested in Genflow for some time. I understand where the company is re the European patent - does anyone know what stage the US patent applications are at? Is it likely that, before any deals with major pharma etc are signed, the IP will need to be in place, particularly in US?

Is there any update re the outstanding grant application? I’ve searched but can’t find anything recent.